<DOC>
	<DOCNO>NCT03052725</DOCNO>
	<brief_summary>This multicenter , open-label ( OL ) extension study obtain additional long-term safety data subcutaneous ( sc ) administration reslizumab treatment administer fix dose 110 mg patient 12 year age old severe eosinophilic asthma complete treatment period placebo-controlled Phase 3 trial sc reslizumab . The study consist screening/baseline visit follow 36-week OL treatment period 15-week follow-up period .</brief_summary>
	<brief_title>A Study Reslizumab Patients 12 Years Age Older With Severe Eosinophilic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Pulmonary Eosinophilia</mesh_term>
	<criteria>• Patient eosinophilic asthma complete treatment period doubleblind , placebo control sc reslizumab study ( Study C38072AS30025 C38072AS30027 ) ~~ Additional criterion apply , please contact investigator information Patient receive reslizumab administration previous clinical trial Studies C38072AS30025 C38072AS30027 . The patient clinically significant , uncontrolled medical condition The patient another confound underlying lung disorder The patient known/diagnosed hypereosinophilic syndrome . The patient diagnosis malignancy within 5 year screen visit , except treat cured nonmelanoma skin cancer . The patient pregnant lactate woman The patient current smoker ( ie , smoke within last 6 month screen ) smoke history ≥10 packyears . The patient currently use systemic immunosuppressive immunomodulatory agent OCS The patient history allergic reaction hypersensitivity component study drug . The patient history immunodeficiency disorder include human immunodeficiency virus ( HIV ) . Additional criterion apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>